Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity
Authors:
- 10 September 2010
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 20 (11) , 1457-1470
Abstract
Importance of the field: Bruton's tyrosine kinase (BTK) has emerged as a new anti-apoptotic molecular target for the treatment of B-lineage leukemias and lymphomas. Preclinical and early clinical results indicate that BTK inhibitors may be useful in the treatment of leukemias and lymphomas. BTK inhibitors may also be helpful in prevention and treatment of thromboembolic complications as well as inflammatory disorders.Areas covered in this review: We provide a comprehensive review of the target diseases for which the use of BTK inhibitors may be helpful as well as the activity profiles of BTK inhibitors.What the reader will gain: We review the currently available translational research, biomarker as well as patent literature regarding BTK molecular target and BTK inhibitors.Take home message: BTK inhibitors may provide the foundation for therapeutic innovation against B-lineage leukemias/lymphomas, inflammatory disorders and autoimmunity.Keywords
This publication has 109 references indexed in Scilit:
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences, 2010
- Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinasesProtein Science, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemiaBlood, 2009
- Tyrosine kinases and their substrates in B lymphocytesImmunological Reviews, 2009
- BLNK suppresses pre–B-cell leukemogenesis through inhibition of JAK3Blood, 2009
- Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cellsBlood, 2006
- Genomic signatures to guide the use of chemotherapeuticsNature Medicine, 2006
- Induction of Immunoglobulin Heavy-Chain Transcription through the Transcription Factor Bright Requires TFII-IMolecular and Cellular Biology, 2006
- Mining the human ‘kinome’Drug Discovery Today, 2002